Paul E
Hautklinik, Klinikum Nürnberg.
Fortschr Med. 1991 Mar 10;109(7):175-8.
Within the framework of a field study, Loratidine (Lisino) was administered to a total of 5,806 patients suffering from pruritic dermatological disorders, i.e. urticaria, neurodermatitis and eczema. As a guideline for the duration of the treatment, a period of three weeks was selected; however, many patients showed a response in a shorter time. The standard dose of loratidine was one 10-mg tablet a day. At the end of the treatment period, 69.6% the urticaria patients were free from pruritus, and 77.6% were free from wheals. In the case of the eczema patients, 47.6% were pruritus-free, while the remaining patients all showed some improvement. In the majority of cases pruritus decreased appreciably after only one hour, but at the latest on the first day of treatment. Treatment with loratidine was tolerated without side effects by 5,593 patients (96.3%).
在一项实地研究的框架内，对总共5806名患有瘙痒性皮肤病（即荨麻疹、神经性皮炎和湿疹）的患者施用了氯雷他定（利司诺）。作为治疗持续时间的指导原则，选择了三周的疗程；然而，许多患者在更短的时间内就有了反应。氯雷他定的标准剂量是每天一片10毫克的片剂。在治疗期结束时，69.6%的荨麻疹患者瘙痒症状消失，77.6%的患者风团消失。对于湿疹患者，47.6%的患者瘙痒症状消失，其余患者均有一定程度的改善。在大多数情况下，瘙痒症状仅在一小时后就明显减轻，但最迟在治疗的第一天。5593名患者（96.3%）耐受氯雷他定治疗且无副作用。
